Search

Your search keyword '"Farkas, Péter"' showing total 254 results

Search Constraints

Start Over You searched for: Author "Farkas, Péter" Remove constraint Author: "Farkas, Péter"
254 results on '"Farkas, Péter"'

Search Results

3. Változások a könnyűlánc-amyloidosis kezelésében – egy nagy budapesti centrum adatai.

6. Myeloma multiplexben szenvedő betegek túlélési eredményei a Semmelweis Egyetem Belgyógyászati és Hematológiai Klinikáján.

7. Semmelweis Egyetem Iron Board – Vaspótlás-konszenzusdokumentum.

11. The Predictive Power of Bosniak 3 and 4 Cystic Renal Lesion Categorization Using Contrast‐Enhanced Ultrasound.

12. Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

13. Hogyan változott az akut myeloid leukaemiás betegek túlélése a terápiás lehetőségek bővülésével az elmúlt 10 évben klinikánkon?

14. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms

15. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

16. Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study)

20. MM-570 Real-World Results With Daratumumab-Bortezomib-Dexamethasone (DVd) Protocol – Or Sometimes Less Might Be More

22. POSTER: AML-588 Advancements in the Diagnosis of Acute Myeloid Leukemia Through the Application of Optical Genome Mapping

23. PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION

26. Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

29. Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

36. Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

38. Európai Sport: Fikció vagy Valóság?

39. Detection of Emerging Ibrutinib Resistance by Flow Cytometry in Patients with Chronic Lymphocytic Leukaemia

40. Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis

43. Familial multiple myeloma. Two more families

45. Detection of Emerging Ibrutinib Resistance by Flow Cytometry in Patients with Chronic Lymphocytic Leukemia

47. Ground motion map of Hungary

48. Concurrent Testing of Spatially Separated Tissue Samples and Circulating Tumor DNA Reveals Substantial Intra-Patient Genetic Heterogeneity in Relapsed/Refractory Follicular Lymphoma

49. Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

Catalog

Books, media, physical & digital resources